Ginsenoside Rc: A potential intervention agent for metabolic syndrome
Journal of Pharmaceutical Analysis · 2023-12 · 13 (12) · 1375-1387
DOI: 10.1016/j.jpha.2023.08.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmaceutical Analysis, 2023-12. Verfasst von Zhengjie Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, 430072, China. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Ginsenoside Rc, a dammarane-type tetracyclic triterpenoid saponin primarily derived from Panax ginseng, has garnered significant attention due to its diverse pharmacological properties. This review outlined the sources, putative biosynthetic pathways, extraction, and quantification techniques, as well as the pharmacokinetic properties of ginsenoside Rc. Furthermore, this study explored the pharmacological effects of ginsenoside Rc against metabolic syndrome (MetS) across various phenotypes including obesity, diabetes, atherosclerosis, non-alcoholic fatty liver disease, and osteoarthritis. It also highlighted the impact of ginsenoside Rc on multiple associated signaling molecules. In conclusion, the anti-MetS effect of ginsenoside Rc is characterized by its influence on multiple organs, multiple targets, and multiple ways. Although clinical investigations regarding the effects of ginsenoside Rc on MetS are limited, its proven safety and tolerability suggest its potential as an effective treatment option.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, 430072, China.
- Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430072, China.
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071, China.
- School of Life Sciences, Hubei University, Wuhan, 430062, China.
Zitieren
APA
Lu, Z., Mao, T., Chen, K., Chai, L., Dai, Y., & Liu, K. (2023). Ginsenoside Rc: A potential intervention agent for metabolic syndrome. Journal of Pharmaceutical Analysis, 13(12), 1375-1387. https://doi.org/10.1016/j.jpha.2023.08.013
Vancouver
Lu Z, Mao T, Chen K, Chai L, Dai Y, Liu K. Ginsenoside Rc: A potential intervention agent for metabolic syndrome. Journal of Pharmaceutical Analysis. 2023;13(12):1375-1387. doi:10.1016/j.jpha.2023.08.013
BibTeX
@article{Lu2023,
author = {Lu, Zhengjie and Mao, Tongyun and Chen, Kaiqi and Chai, Longxin and Dai, Yongguo and Liu, Kexin},
title = {Ginsenoside Rc: A potential intervention agent for metabolic syndrome},
journal = {Journal of Pharmaceutical Analysis},
year = {2023},
volume = {13},
number = {12},
pages = {1375--1387},
doi = {10.1016/j.jpha.2023.08.013}
}
EUVIMED